{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:34:29Z","timestamp":1780461269368,"version":"3.54.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.jaad.2018.05.030","type":"journal-article","created":{"date-parts":[[2018,5,25]],"date-time":"2018-05-25T03:54:42Z","timestamp":1527220482000},"page":"1034-1038.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Oral diabetes medications other than dipeptidyl peptidase 4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study"],"prefix":"10.1016","volume":"79","author":[{"given":"Outi","family":"Varpuluoma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Kaisa","family":"F\u00f6rsti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jari","family":"Jokelainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miia","family":"Turpeinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markku","family":"Timonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaisa","family":"Tasanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Huilaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jaad.2018.05.030_bib1","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.autrev.2017.03.010","article-title":"Bullous pemphigoid","volume":"16","author":"Ba\u011fc\u0131","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"31","key":"10.1016\/j.jaad.2018.05.030_bib2","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1111\/jdv.14312","article-title":"Multimorbidity in bullous pemphigoid: a case-control analysis of bullous pemphigoid patients with age- and gender-matched controls","volume":"10","author":"Sim","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.jaad.2018.05.030_bib3","first-page":"758","article-title":"Risk of death in bullous pemphigoid: a retrospective database study in Finland","volume":"96","author":"F\u00f6rsti","year":"2016","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2018.05.030_bib4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/2013.jamadermatol.376","article-title":"The associations between bullous pemphigoid and drug use: a UK case-control study","volume":"149","author":"Lloyd-Lavery","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2018.05.030_bib5","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.jid.2018.01.027","article-title":"Vildagliptin significantly increases the risk of bullous pemphigoid: a Finnish nationwide registry study","volume":"7","author":"Varpuluoma","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2018.05.030_bib6","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/bjd.14601","article-title":"Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database","volume":"175","author":"Bene","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.05.030_bib7","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jaad.2017.12.038","article-title":"Dipeptidyl peptidase-IV inhibitors, a risk factor for bullous pemphigoid. Retrospective multicenter case-control study in France and Switzerland","volume":"78","author":"Benzaquen","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.05.030_bib8","doi-asserted-by":"crossref","first-page":"37125","DOI":"10.1038\/srep37125","article-title":"Psychiatric and neurological disorders are associated with bullous pemphigoid\u2014a nationwide Finnish Care Register study","volume":"6","author":"F\u00f6rsti","year":"2016","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.jaad.2018.05.030_bib9","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1111\/bjd.15405","article-title":"Increased frequency of multiple sclerosis among patients with bullous pemphigoid: a population-based cohort study on comorbidities anchored around the diagnosis of bullous pemphigoid","volume":"176","author":"Kibsgaard","year":"2017","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.05.030_bib10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/bjd.14821","article-title":"Hospitalization, inpatient burden and comorbidities associated with bullous pemphigoid in the USA","volume":"176","author":"Ren","year":"2017","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2018.05.030_bib11","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/bjd.15195","article-title":"The association between drugs and bullous pemphigoid","volume":"176","author":"Tan","year":"2017","journal-title":"Br J Dermatol"},{"issue":"suppl 1","key":"10.1016\/j.jaad.2018.05.030_bib12","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.2337\/dc17-S011","article-title":"8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142018","volume":"40","author":"American Diabetes Association","year":"2017","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.jaad.2018.05.030_bib13","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/exd.13401","article-title":"Neurological and psychiatric associations in bullous pemphigoid\u2014more than skin deep?","volume":"26","author":"F\u00f6rsti","year":"2017","journal-title":"Exp Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2018.05.030_bibS1","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/archderm.134.4.465","article-title":"High risk of death in elderly patients with extensive bullous pemphigoid","volume":"134","author":"Roujeau","year":"1998","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2018.05.030_bibS2","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jaad.2008.07.022","article-title":"Mortality of bullous pemphigoid: an evaluation of 223 patients and comparison with the mortality in the general population in the United States","volume":"59","author":"Parker","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.05.030_bibS3","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1684\/ejd.2010.0805","article-title":"Bullous pemphigoid and internal diseases\u2014a case-control study","volume":"20","author":"Jedlickova","year":"2010","journal-title":"Eur J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2018.05.030_bibS4","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1365-2133.2011.10413.x","article-title":"Mortality of bullous pemphigoid in Switzerland: a prospective study","volume":"165","author":"Cortes","year":"2011","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2018.05.030_bibS5","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/jid.2010.301","article-title":"Risk factors for bullous pemphigoid in the elderly: a prospective case-control study","volume":"131","author":"Bastuji-Garin","year":"2011","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2018.05.030_bibS6","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/jdv.12065","article-title":"Mortality of bullous pemphigoid in the first year after diagnosis: a retrospective study in a Spanish medical centre","volume":"28","author":"Gual","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2018.05.030_bibS7","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1159\/000345625","article-title":"Mortality rate in bullous pemphigoid: a retrospective monocentric cohort study","volume":"225","author":"Cortes","year":"2012","journal-title":"Dermatology"},{"issue":"1","key":"10.1016\/j.jaad.2018.05.030_bibS8","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1001\/archdermatol.2012.2994","article-title":"Mortality of bullous pemphigoid in China","volume":"149","author":"Li","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2018.05.030_bibS9","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/bjd.12806","article-title":"Mortality of bullous pemphigoid in Singapore: risk factors and causes of death in 359 patients seen at the National Skin Centre","volume":"170","author":"Cai","year":"2014","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2018.05.030_bibS10","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1590\/abd1806-4841.20142516","article-title":"Bullous pemphigoid and comorbidities: a case-control study in Portuguese patients","volume":"89","author":"Teixeira","year":"2014","journal-title":"An Bras Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2018.05.030_bibS11","first-page":"758","article-title":"Risk of death in bullous pemphigoid: a retrospective database study in Finland","volume":"96","author":"F\u00f6rsti","year":"2016","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2018.05.030_bibS12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/bjd.14821","article-title":"Hospitalization, inpatient burden and comorbidities associated with bullous pemphigoid in the USA","volume":"176","author":"Ren","year":"2017","journal-title":"Br J Dermatol"},{"issue":"31","key":"10.1016\/j.jaad.2018.05.030_bibS13","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1111\/jdv.14312","article-title":"Multimorbidity in bullous pemphigoid: a case-control analysis of bullous pemphigoid patients with age- and gender-matched controls","volume":"10","author":"Sim","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.jaad.2018.05.030_bibS14","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1111\/bjd.15405","article-title":"Increased frequency of multiple sclerosis among patients with bullous pemphigoid: a population-based cohort study on comorbidities anchored around the diagnosis of bullous pemphigoid","volume":"176","author":"Kibsgaard","year":"2017","journal-title":"Br J Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218308260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218308260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:46:54Z","timestamp":1759272414000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962218308260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0190962218308260"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2018.05.030","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral diabetes medications other than dipeptidyl peptidase 4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2018.05.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}